Compare Bath & Body Works Inc (BBWI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Neurocrine Biosciences Inc — how do they compare? Bath & Body Works Inc trades at $19.4 (market cap $4.12B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.51B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.3× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 3.92% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BBWI | NBIX | |
|---|---|---|
Market Cap | $4.12B | $17.51B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.11 | $180.55 |
52-Week Low | $14.85 | $123.10 |
Enterprise Value | $8.01B | $16.60B |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $20.42, up 0.44% today, with a bearish technical signal but attractive valuation metrics including a P/E of 5.8 and P/S of 0.58. Recent earnings show mixed quarterly beats, with Q1 2026 exceeding expectations. The company maintains solid profitability with a 10.03% net income margin and positive cash flow trends projected for 2026. Strategic initiatives include a new Ulta Beauty partnership and international expansion to drive growth amid declining revenue trends.
Outlook: BBWI presents a value opportunity with deep valuation discounts and operational strengths, though persistent revenue declines and high debt pose risks. Analyst consensus is cautiously optimistic with a $22 price target, suggesting modest upside potential if turnaround efforts gain traction against competitive and macroeconomic headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
